Kenneth J Moise1, Pedro S Argoti. 1. Department of Obstetrics, Gynecology and Reproductive Sciences, UT Health-The University of Texas Health Science Center at Houston, and the Texas Fetal Center, Children's Memorial Hermann Hospital, Houston, Texas 77030, USA. Kenneth.J.Moise@uth.tmc.edu
Abstract
OBJECTIVE: To evaluate the application of new technologies to the management of the red cell alloimmunized pregnancy. DATA SOURCES: We searched three computerized databases for studies that described treatment or prevention of alloimmunization in pregnancy (MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials [1990 to July 2012]). The text words and MeSH included Rhesus alloimmunization, Rhesus isoimmunization, Rhesus prophylaxis, Rhesus disease, red cell alloimmunization, red cell isoimmunization, and intrauterine transfusion. METHODS OF STUDY SELECTION: Of the 2,264 studies initially identified, 246 were chosen after limiting the review to those articles published in English and crossreferencing to eliminate duplication. TABULATION, INTEGRATION, AND RESULTS: Both authors independently reviewed the articles to eliminate publications involving less than six patients. Special emphasis was given to publications that have appeared since 2008. CONCLUSION: Quantitative polymerase chain reaction can be used instead of serology to more accurately determine the paternal RHD zygosity. In the case of unknown or a heterozygous paternal RHD genotype, new DNA techniques now make it possible to diagnose the fetal blood type through cell-free fetal DNA in maternal plasma. Serial Doppler assessment of the peak systolic velocity in the middle cerebral artery is now the standard to detect fetal anemia and determine the need for the first intrauterine transfusion. Assessment of the peak systolic velocity in the middle cerebral artery can be used to time the second transfusion, but its use to decide when to perform subsequent procedures awaits further study. New data suggest normal neurologic outcome in 94% of cases after intrauterine transfusion, although severe hydrops fetalis may be associated with a higher risk of impairment. Recombinant Rh immune globulin is on the horizon. Cell-free fetal DNA for fetal RHD genotyping may be used in the future to decide which patients should receive antenatal Rh immune globulin.
OBJECTIVE: To evaluate the application of new technologies to the management of the red cell alloimmunized pregnancy. DATA SOURCES: We searched three computerized databases for studies that described treatment or prevention of alloimmunization in pregnancy (MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials [1990 to July 2012]). The text words and MeSH included Rhesus alloimmunization, Rhesus isoimmunization, Rhesus prophylaxis, Rhesus disease, red cell alloimmunization, red cell isoimmunization, and intrauterine transfusion. METHODS OF STUDY SELECTION: Of the 2,264 studies initially identified, 246 were chosen after limiting the review to those articles published in English and crossreferencing to eliminate duplication. TABULATION, INTEGRATION, AND RESULTS: Both authors independently reviewed the articles to eliminate publications involving less than six patients. Special emphasis was given to publications that have appeared since 2008. CONCLUSION: Quantitative polymerase chain reaction can be used instead of serology to more accurately determine the paternal RHD zygosity. In the case of unknown or a heterozygous paternal RHD genotype, new DNA techniques now make it possible to diagnose the fetal blood type through cell-free fetal DNA in maternal plasma. Serial Doppler assessment of the peak systolic velocity in the middle cerebral artery is now the standard to detect fetal anemia and determine the need for the first intrauterine transfusion. Assessment of the peak systolic velocity in the middle cerebral artery can be used to time the second transfusion, but its use to decide when to perform subsequent procedures awaits further study. New data suggest normal neurologic outcome in 94% of cases after intrauterine transfusion, although severe hydrops fetalis may be associated with a higher risk of impairment. Recombinant Rh immune globulin is on the horizon. Cell-free fetal DNA for fetal RHD genotyping may be used in the future to decide which patients should receive antenatal Rh immune globulin.
Authors: Prabitha Natarajan; Jingchun Liu; Manjula Santhanakrishnan; David R Gibb; Lewis M Slater; Jeanne E Hendrickson Journal: Transfusion Date: 2016-10-13 Impact factor: 3.157
Authors: Sean R Stowell; Kathryn R Girard-Pierce; Nicole H Smith; Kate L Henry; C Maridith Arthur; James C Zimring; Jeanne E Hendrickson Journal: Transfusion Date: 2013-04-29 Impact factor: 3.157
Authors: Pablo Cure; Melania Bembea; Stella Chou; Allan Doctor; Anne Eder; Jeanne Hendrickson; Cassandra D Josephson; Alan E Mast; William Savage; Martha Sola-Visner; Philip Spinella; Simon Stanworth; Marie Steiner; Traci Mondoro; Shimian Zou; Catherine Levy; Myron Waclawiw; Nahed El Kassar; Simone Glynn; Naomi L C Luban Journal: Transfusion Date: 2017-03-28 Impact factor: 3.157
Authors: Carolina Trucco Boggione; Melina E Luján Brajovich; Stella M Mattaloni; René A Di Mónaco; Silvia E García Borrás; Claudia S Biondi; Carlos M Cotorruelo Journal: Blood Transfus Date: 2016-03-21 Impact factor: 3.443